Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1443700 | 0.75 | CYP2D6 (0.41) | GLO1CYP2D6CYP2C19ALDH1A1NPSR1 | |
| SCHEMBL1443696 | 0.75 | CYP2D6 (0.41) | GLO1CYP2D6CYP2C19ALDH1A1NPSR1 | |
| SCHEMBL1877802 | 0.74 | — | — | |
| SCHEMBL12883891 | 0.74 | CYP2D6 (0.32) | CYP2D6CYP2C19 | |
| SCHEMBL8849808 | 0.73 | CYP2D6 (0.40) | GLO1CYP2D6CYP2C19NPSR1 | |
| SCHEMBL15046186 | 0.72 | — | — | |
| SCHEMBL19139320 | 0.71 | CYP2D6 (0.34) | GLO1CYP2D6CYP2C19 | |
| SCHEMBL4052324 | 0.71 | CYP1A2 (0.33) | ALDH1A1 | |
| SCHEMBL14978030 | 0.70 | GLO1 (0.33) | GLO1CYP2D6CYP2C19 | |
| SCHEMBL16218849 | 0.70 | GLO1 (0.33) | GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | disclosed |
| US-12539332-B2 | Anti-viral and hepatic-targeted drugs | A-BIOPHARMA (FR) | 2026-02-03 | — | — | US | disclosed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | disclosed |
| EP-4045504-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | Ai-biopharma (FR) | 2022-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539332-B2 | Anti-viral and hepatic-targeted drugs | HAVCR2, NR1H4, NR1H3 | GLO1 4494/4885CYP2D6 129/4885CYP2C19 3557/4885 |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | GLO1 4283/4885CYP2D6 136/4885CYP2C19 3542/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | GLO1 2771/4885CYP2D6 155/4885CYP2C19 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.